Back to top
more

CureVac (CVAC)

(Real Time Quote from BATS)

$2.76 USD

2.76
62,648

+0.05 (1.85%)

Updated Nov 5, 2024 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More

by Zacks Equity Research

The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).

CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study

by Zacks Equity Research

CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.

Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.

CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data

by Zacks Equity Research

CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.

Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.

CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine

by Zacks Equity Research

CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

Novartis (NVS) & Molecular Partners Initiate Study for COVID-19

by Zacks Equity Research

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology

by Zacks Equity Research

The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology

Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response

by Zacks Equity Research

Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.

Neena Mishra headshot

Best Biotech Stocks & ETFs for mRNA, Gene Editing

by Neena Mishra

Here is what you should know about investing in these life changing technologies.

Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes

by Zacks Equity Research

Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.

Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra

by Zacks Equity Research

Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.

Biotech Stock Roundup: REGN Cocktail Data Positive, INCY's Jakafi Disappoints & More

by Zacks Equity Research

The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Regeneron (REGN) and Incyte (INCY).

Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine

by Zacks Equity Research

Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.

Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY

by Zacks Equity Research

The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.

CureVac (CVAC) Up on Deal With Bayer for COVID-19 Vaccine

by Zacks Equity Research

CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.

Kinjel Shah headshot

4 Small COVID-19 Vaccine Makers to Look Out for in 2021

by Kinjel Shah

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

Company News for Dec 15, 2020

by Zacks Equity Research

Companies In The News Are: BA, ALXN, AZN, CVAC, GOOGL.

CureVac (CVAC) Begins Pivotal Study on COVID-19 Vaccine

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.

Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine

by Zacks Equity Research

Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.

Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study

by Zacks Equity Research

Vaxart (VXRT) doses the first subject in an early-stage study of its oral coronavirus vaccine candidate VXA-CoV2-1. Stock rises.

Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.